Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry.
David L. Grinblatt(NorthShore University HealthSystem), Kristen Sullivan(Tufts University), Mohit Narang(Gettysburg College), James Malone(Bigfoot Biomedical (United States)), Tim S. Dunne, David A. Sweet
Cited by 8
Related Papers
ArrayExpress update--from an archive of functional genomics experiments to the atlas of gene expression
|Nucleic Acids Research|2008|424
ArrayExpress update--an archive of microarray and high-throughput sequencing-based functional genomics experiments
|Nucleic Acids Research|2010|337
Gene Expression Atlas update--a value-added database of microarray and sequencing-based functional genomics experiments
|Nucleic Acids Research|2011|165
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review
|European Journal of Heart Failure|2020|118
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA<sup>®</sup>registry
|Leukemia & lymphoma/Leukemia and lymphoma|2014|40